WO2018051471A1 - Inhibiteur d'accumulation de graisse, inhibiteur de différenciation de pré-adipocytes, agent de réduction de graisse viscérale et aliment ou boisson pour la réduction de graisse viscérale - Google Patents

Inhibiteur d'accumulation de graisse, inhibiteur de différenciation de pré-adipocytes, agent de réduction de graisse viscérale et aliment ou boisson pour la réduction de graisse viscérale Download PDF

Info

Publication number
WO2018051471A1
WO2018051471A1 PCT/JP2016/077315 JP2016077315W WO2018051471A1 WO 2018051471 A1 WO2018051471 A1 WO 2018051471A1 JP 2016077315 W JP2016077315 W JP 2016077315W WO 2018051471 A1 WO2018051471 A1 WO 2018051471A1
Authority
WO
WIPO (PCT)
Prior art keywords
fat
iodine
egg
visceral
inhibitor
Prior art date
Application number
PCT/JP2016/077315
Other languages
English (en)
Japanese (ja)
Inventor
次郎 横山
恵美 森岡
Original Assignee
日本農産工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日本農産工業株式会社 filed Critical 日本農産工業株式会社
Priority to PCT/JP2016/077315 priority Critical patent/WO2018051471A1/fr
Priority to KR1020197010469A priority patent/KR102239331B1/ko
Priority to JP2018539460A priority patent/JP6752285B2/ja
Publication of WO2018051471A1 publication Critical patent/WO2018051471A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L15/00—Egg products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L15/00—Egg products; Preparation or treatment thereof
    • A23L15/30—Addition of substances other than those covered by A23L15/20 – A23L15/25
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss

Definitions

  • the present disclosure relates to a fat accumulation inhibitor, an agent for inhibiting differentiation of preadipocytes, a visceral fat reducing agent, and a food and drink for reducing visceral fat.
  • Adipocytes are cells that originate from mesodermal stem cells and differentiate through fat precursor cells, etc., and are classified into white adipocytes that control fat synthesis, accumulation, and release, and brown adipocytes that control heat production.
  • Obesity is a condition where excessive fat is accumulated in white fat cells. Therefore, in order to prevent or improve obesity, it is effective to suppress fat accumulation in white adipocytes. In recent years, it has been clarified that the number of white adipocytes also increases after adulthood, and in order to prevent or ameliorate obesity, it is also possible to suppress the differentiation of preadipocytes into white adipocytes. It is valid.
  • visceral fat obesity is roughly classified into subcutaneous fat type obesity and visceral fat type obesity.
  • visceral fat obesity is known to increase the risk of diabetes, arteriosclerosis, hypertension, cerebral infarction, dyslipidemia and the like. For this reason, it is important to prevent or improve visceral fat type obesity among obesity.
  • Patent Document 1 describes an adipocyte fat accumulation inhibitor containing an aqueous ethanol extract of Kawaratake as an active ingredient.
  • Patent Document 2 describes a preadipocyte differentiation inhibitor containing lotus germ and yacon extracts, and an anti-obesity agent containing this differentiation inhibitor as an active ingredient.
  • Patent Document 3 describes a body fat accumulation inhibitor, visceral fat accumulation inhibitor and the like containing egg white as an active ingredient.
  • the body fat accumulation inhibitor and visceral fat accumulation inhibitor described in Patent Document 3 contain food materials as active ingredients, and are considered to be excellent in safety when continuously administered or ingested. However, the effect is not sufficient, and a search for a new active ingredient that is effective and excellent in safety has been desired.
  • the present disclosure provides a novel fat accumulation inhibitor, an adipose precursor cell differentiation inhibitor, a visceral fat reducing agent, and a food and drink for reducing visceral fat using an effective ingredient that is effective and excellent in safety. Is an issue.
  • a fat accumulation inhibitor comprising, as an active ingredient, an egg containing 4.2 mass ppm or more of iodine.
  • An agent for inhibiting differentiation of adipose precursor cells comprising as an active ingredient an egg containing 4.2 mass ppm or more of iodine.
  • a visceral fat reducing agent comprising, as an active ingredient, an egg containing 4.2 ppm by mass or more of iodine.
  • a food or drink for reducing visceral fat comprising an egg containing 4.2 ppm by mass or more of iodine as an active ingredient.
  • a visceral fat reducing agent that is used so that an egg yolk extract containing an iodinated peptide is an active ingredient and is administered in an amount of 300 ⁇ g or more per day.
  • a novel fat accumulation inhibitor an adipose precursor cell differentiation inhibitor, a visceral fat reducing agent, and a food and drink for reducing visceral fat using an effective ingredient that is effective and excellent in safety. Can do.
  • FIG. 5 is a graph showing the glycerol-3-phosphate dehydrogenase (GPDH) activity of adipocytes when an egg yolk extract (IY) containing high iodine content or an egg yolk extract (OY) of normal egg is added to the medium. is there.
  • GPDH glycerol-3-phosphate dehydrogenase
  • FIG. It is a figure which shows the expression level (relative value) of the adipogenin gene of an adipocyte when the egg yolk extract (IY) or egg yolk extract (OY) of a normal egg is added in a culture medium. It is a figure which shows the expression level (relative value) of the leptin gene of an adipocyte when the egg yolk extract (IY) or egg yolk extract (OY) of a normal egg is added in a culture medium. It is a figure which shows the expression level (relative value) of the adiponectin gene of an adipocyte when the egg yolk extract (IY) or egg yolk extract (OY) of a normal egg is added in a culture medium.
  • PPAR Peroxisome Proliferator Activated Receptor
  • a numerical range indicated by using “to” indicates a range including the numerical values described before and after “to” as the minimum value and the maximum value, respectively.
  • the fat accumulation inhibitor, the precursor of preadipocytes, the visceral fat reducing agent, and the food and drink for reducing visceral fat according to the first embodiment are all eggs containing 4.2 ppm by mass or more of iodine (hereinafter referred to as “bird eggs”). , Also referred to as “iodine-rich egg”) as an active ingredient.
  • Examples of avian eggs include chicken eggs such as chickens, rabbits, rib chickens and ducks, with chicken eggs being preferred. Eggs with high iodine content can be obtained by feeding birds with an increased iodine content by blending an iodine source and increasing the iodine content in the eggs.
  • iodine sources include iodine compounds such as calcium iodate, potassium iodate, potassium iodide, sodium iodate, thymol iodide, copper iodide, hypoiodosalicylic acid, calcium periodate, calcium iodobihemate; Examples include seaweeds containing a high content of iodine such as kelp or processed products thereof.
  • the rate of migration of iodine to eggs, etc. it is preferable to use at least one selected from the group consisting of calcium iodate, potassium iodate, and potassium iodide as the iodine source. Moreover, it is more preferable to use a seaweed together with at least one selected from the group consisting of calcium iodate, potassium iodate, and potassium iodide.
  • the amount of iodine given to birds can be adjusted as appropriate depending on the type of bird.
  • the iodine intake is preferably 5 mg to 250 mg per bird per day, and more preferably 5 mg to 15 mg iodine per bird per day.
  • the iodine content in the feed is preferably 50 mass ppm to 2500 mass ppm, more preferably 50 mass ppm to 150 mass ppm. It is more preferable.
  • the target high-iodine egg is produced after about one week.
  • a feed containing about 50 ppm by mass of iodine is given to a laying hen, eggs containing about 300 ⁇ g of iodine per piece are produced.
  • the iodine content of the high-iodine egg is not particularly limited as long as it is 4.2 mass ppm or more with respect to the total amount of the edible portion, and is preferably 4.2 mass ppm to 20.0 mass ppm, for example.
  • the iodine content of the high-iodine egg is not particularly limited as long as it is 4.2 mass ppm or more with respect to the total amount of the edible portion, and is preferably 4.2 mass ppm to 20.0 mass ppm, for example.
  • a decrease in the egg-laying rate tends to be suppressed.
  • the edible part of shell eggs circulated mainly in the market is about 45 to 66 g per piece
  • the iodine content of 4.2 to 20.0 ppm by weight is about 200 ⁇ g per piece.
  • the required amount of iodine in egg-laying hens is 0.2 mg per 1 kg of feed (according to Japanese feed standard poultry (2011 version)), and the actual iodine content in commercially available feed is 0.3 mg to 2.0 mg per 1 kg of feed. It has become.
  • the iodine content of normal eggs produced from laying hens bred using this commercial feed is about 9 ⁇ g per piece (according to the Japanese Food Standards Ingredients 2015 edition (7th edition)), at most one piece. About 30 ⁇ g per unit.
  • ⁇ ⁇ ⁇ Eggs with high iodine content are also available as commercial products.
  • “Iodo Egg Light” (“Iodo Egg” is a registered trademark) of Nippon Agricultural Industry Co., Ltd. can be mentioned.
  • the fat accumulation inhibitor, the preadipocyte differentiation inhibitor, the visceral fat reducing agent, and the food and drink for reducing visceral fat according to the first embodiment may contain the whole egg of an iodine-rich egg as an active ingredient. Further, since most of iodine in the egg containing high iodine is contained in the yolk as an iodide peptide bound to the peptide, the fat accumulation inhibitor, the precursor of fat precursor cells, the visceral fat reduction according to the first embodiment.
  • the agent and food and drink for reducing visceral fat may contain egg yolk of a high iodine content egg as an active ingredient, or may contain an egg yolk extract as an active ingredient.
  • the egg yolk extract is not particularly limited as long as it contains an iodide peptide in egg yolk.
  • the whole egg, egg yolk, and egg yolk extract of the egg with high iodine content may be subjected to treatments such as drying, concentration, powdering, and granulating as necessary.
  • the dosage form of the fat accumulation inhibitor, the adipocyte differentiation inhibitor, and the visceral fat reducing agent of the first embodiment is not particularly limited, and examples thereof include powders, granules, tablets, capsules, syrups, and emulsions. .
  • the fat accumulation inhibitor, the preadipocyte differentiation inhibitor, and the visceral fat-reducing agent of the first embodiment further contain various excipients, binders, disintegrants, solvents, and the like depending on the dosage form. May be.
  • the dose and administration period of the fat accumulation inhibitor of the first embodiment, the differentiation inhibitor of preadipocytes, and the visceral fat reducing agent, and the intake and intake period of the food and drink for reducing visceral fat of the first embodiment are: There is no particular limitation as long as the intended effect is achieved. As an example, it is preferable to continue the dose or intake amount for which the iodine amount per day is 300 ⁇ g or more for 1 month or more, and it is more preferable to continue for 3 months or more.
  • the upper limit of the dose or intake can be set based on the tolerable upper limit of iodine. As an example, the amount of iodine per day can be set to a dose or intake amount of 3000 ⁇ g or less.
  • the obesity is prevented or improved by administering the fat accumulation inhibitor of the first embodiment, the differentiation inhibitor of preadipocytes, or the visceral fat reducing agent, or taking the food or drink for reducing visceral fat of the first embodiment.
  • the following method is also provided. (1) A method for inhibiting fat accumulation, comprising administering an effective amount of a bird egg containing iodine of 4.2 mass ppm or more to a subject. (2) A method for inhibiting differentiation of preadipocytes, comprising administering to a subject an effective amount of an egg containing 4.2 mass ppm or more of iodine.
  • a visceral fat reduction method comprising administering to a subject an effective amount of an egg containing 4.2 ppm by mass or more of iodine.
  • a visceral fat reduction method comprising ingesting an effective amount of an egg containing 4.2 ppm by mass or more of iodine.
  • a method for preventing or improving obesity comprising administering to a subject an effective amount of a bird egg containing iodine of 4.2 mass ppm or more.
  • a method for preventing or improving obesity comprising ingesting an effective amount of a bird egg containing iodine of 4.2 mass ppm or more.
  • the visceral fat reducing agent according to the second embodiment is used so that egg yolk extract containing an iodinated peptide is an active ingredient and is administered in an amount of 300 ⁇ g or more per day.
  • the eggs include chicken eggs such as chickens, rabbits, rib chickens and ducks, and chicken eggs are preferred.
  • the bird egg may be a normal egg or the above-described high-iodine egg, and the above-described high-iodine egg is preferable in terms of high iodine content.
  • the egg yolk extract is not particularly limited as long as it contains an iodide peptide in egg yolk.
  • the egg yolk extract may be subjected to treatments such as drying, concentration, pulverization, and granulation as necessary.
  • the dosage form of the visceral fat reducing agent of the second embodiment is not particularly limited, and examples thereof include powders, granules, tablets, capsules, syrups, and emulsions.
  • the visceral fat reducing agent of the second embodiment may further contain various excipients, binders, disintegrants, solvents and the like depending on the dosage form.
  • the dose of the visceral fat reducing agent according to the second embodiment is not particularly limited as long as the dose per day is 300 ⁇ g or more.
  • the upper limit value of the dose can be set based on the tolerable upper limit amount of iodine. As an example, it can be set as the dosage which the iodine amount per day will be 3000 micrograms or less.
  • the administration period of the visceral fat reducing agent of the second embodiment is not particularly limited as long as the intended effect is exhibited. As an example, it is preferable to administer continuously for 1 month or more, and it is more preferable to administer continuously for 3 months or more.
  • a visceral fat reduction method comprising administering 300 ⁇ g or more of an egg yolk extract containing an iodinated peptide as an iodine amount per day.
  • a method for preventing or improving obesity comprising administering 300 ⁇ g or more of an egg yolk extract containing an iodinated peptide as iodine amount per day.
  • mice fat precursor cells 3T3-L1 were differentiated into adipocytes, and the amount of fat accumulated in the adipocytes was measured.
  • 3T3-L1 cells usually show fibroblast-like morphology under culture conditions, but form insulin granules and differentiate into adipocytes by applying insulin stimulation after confluence. .
  • 3T3-L1 cells were seeded in a 6-well plate and maintained by DMEM (Dulbecco's Modified Modified Eagle Medium) containing 10 v / v% FBS (Fetal Bovine Serum) until 2 days after confluence. The medium was changed every 48 hours. Next, the medium was changed to DMEM containing 10 v / v% FBS, 0.5 mM isobutylmethylxanthine, 1 ⁇ M dexamethasone, and 1.7 ⁇ M insulin, and differentiation into adipocytes was induced by culturing for 48 hours. Subsequently, the medium was replaced with DMEM containing 10 v / v% FBS.
  • DMEM Dulbecco's Modified Modified Eagle Medium
  • FBS Fetal Bovine Serum
  • egg yolk extract (IY) containing high iodine content or egg yolk extract (OY) of normal egg was added to a final concentration of 5 ⁇ g / mL, 10 ⁇ g / mL, or 50 ⁇ g / mL, and cultured for 10 days. .
  • the medium was changed every 48 hours.
  • adipocytes After 10 days of culture, the differentiated adipocytes were washed 3 times with PBS and fixed with 10 v / v% paraformaldehyde solution for 10 minutes or more. After fixation, adipocytes were washed twice with PBS and stained with 0.5 w / v% Oil Red O solution (Sigma-Aldrich) at 37 ° C. Thereafter, the amount of fat accumulated in the fat cells was evaluated by measuring the absorbance at a wavelength of 570 nm.
  • FIG. 1 shows the evaluation results of the amount of accumulated fat in fat cells.
  • IY egg yolk extract
  • OY egg yolk extract
  • Example 2 In Experimental Example 2, the amount of fat accumulated in fat cells was measured in the same manner as in Example 1 except that sodium iodide was used instead of the egg yolk extract. Sodium iodide was added to the medium so that the final concentration of iodide ions was 10 ⁇ 9 M, 10 ⁇ 8 M, 10 ⁇ 7 M, or 10 ⁇ 6 M.
  • Fig. 2 shows the evaluation results of the amount of accumulated fat in fat cells. As shown in FIG. 2, even when sodium iodide was added to the medium, the amount of fat accumulated in the fat cells did not change significantly. From the results of Experimental Examples 1 and 2, the fat accumulation suppression effect by the egg yolk extract (IY) of the high iodine content egg is not due to iodine in an ionic state, but due to the iodide peptide contained in the high iodine content egg. It is suggested that there is.
  • IY egg yolk extract
  • 3T3-L1 was prepared using a medium supplemented with egg yolk extract (IY) containing high iodine content or egg yolk extract (OY) of normal egg to a final concentration of 50 ⁇ g / mL.
  • the cells were cultured for 10 days to obtain adipocytes.
  • the adipocytes (Day 10) after 10 days of culturing were washed with PBS, the cells were crushed, and GPDH activity was measured for the cell lysate using a GPDH activity measurement kit (Cell Garage).
  • the obtained measurement results were corrected with the amount of protein in the cell disruption solution.
  • GPDH activity was also measured in the same manner for cells (Day 0) before 10 days of culture.
  • Fig. 3 shows the measurement results of GPDH activity.
  • the GPDH activity was compared to the case where the egg yolk extract (OY) of normal egg was added to the medium. Significantly decreased (p ⁇ 0.05).
  • 3T3-L1 was prepared using a medium supplemented with egg yolk extract (IY) containing high iodine content or egg yolk extract (OY) of normal egg to a final concentration of 50 ⁇ g / mL.
  • the cells were cultured for 10 days to obtain adipocytes.
  • Total RNA was extracted from adipocytes (Day 10) after 10 days of culture, and the expression level of each gene of PPAR- ⁇ 2, adipogenin, leptin, and adiponectin was measured by real-time reverse transcription PCR (Polymerase Chain ⁇ ⁇ ⁇ ⁇ Reaction) according to a conventional method. did.
  • the obtained measurement results were corrected with the expression level of ⁇ -actin gene as an internal standard. For comparison, the expression level of the gene was measured in the same manner for the cells (Day 0) before 10 days of culture.
  • FIGS. 4A to 4D show the measurement results (relative values) of the expression levels of each gene of PPAR- ⁇ 2, adipogenin, leptin, and adiponectin.
  • “ND” in FIGS. 4A to 4C means no detection.
  • FIGS. 4A to 4D when the egg yolk extract (IY) containing high iodine content is added to the medium, it is compared with the case where the egg yolk extract (OY) of normal egg is added to the medium.
  • PPAR- ⁇ 2 adipogenin, leptin, and adiponectin genes were significantly reduced (PPAR- ⁇ 2, adipogenin, and leptin: p ⁇ 0.05, adiponectin: p ⁇ 0.1).
  • Example 5 In Experimental Example 5, the subjects were divided into two groups to continuously ingest iodine-rich eggs or normal eggs, and the effect on body fat was evaluated by the double blind method. Eggs containing about 1300 ⁇ g of iodine per 100 g of edible portion (Nippon Agricultural Industrial Co., Ltd., “Iodo Egg Light”) were used as eggs with high iodine content. In addition, commercially available eggs were used as normal eggs.
  • the subjects were 56 men and women who were between 40 and 65 years old and had a BMI (Body Mass Index) of 25 kg / m 2 or more and less than 30 kg / m 2 , and the test group (male: 14 and female: 14) and the control group ( The group was divided into two groups: 14 males and 14 females.
  • the test group one iodine-rich egg per day was continuously ingested as a boiled egg for 12 weeks.
  • the control group 1 normal egg per day was continuously ingested as a boiled egg over 12 weeks.
  • various tests such as a blood test and a urine test, were performed and compared before and after the test.
  • Table 1 shows changes in the total fat area, visceral fat area, and subcutaneous fat area before and after the test.
  • Table 1 also shows blood total cholesterol (T-cho), triglyceride (TG), LDL (Low Density Lipoprotein) cholesterol (LDL-cho), HDL (High Density Lipoprotein) cholesterol (HDL-cho), free
  • T-cho blood total cholesterol
  • TG triglyceride
  • LDL Low Density Lipoprotein
  • HDL High Density Lipoprotein cholesterol
  • Table 1 shows the average value ⁇ standard error for each group.
  • the amount of total cholesterol, triglyceride, LDL cholesterol, and HDL cholesterol in blood related to lipid metabolism did not change significantly in either the test group or the control group.
  • the amounts of free triiodothyronine (FT3) and free thyroxine (FT4) in blood related to thyroid function did not change significantly in either the test group or the control group, and remained within the normal range. From these results, the visceral fat reduction effect by the iodine-rich egg is not due to the improvement of lipid metabolism function or thyroid function, but to the iodide peptide contained in the iodine-rich egg. It is suggested.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Meat, Egg Or Seafood Products (AREA)

Abstract

L'invention concerne un inhibiteur d'accumulation de graisse, un inhibiteur de différenciation de pré-adipocytes, un agent de réduction de graisse viscérale et un aliment ou une boisson pour la réduction de graisse viscérale qui contiennent chacun, en tant que principe actif, un oeuf d'oiseau contenant de l'iode dans une quantité de 4,2 ppm en masse ou plus. L'invention concerne également un agent de réduction de graisse viscérale qui contient, en tant que principe actif, un extrait du jaune d'oeuf d'un oeuf d'oiseau contenant un peptide iodé et qui est administré en une dose de 300 μg ou plus par jour en termes de quantité d'iode.
PCT/JP2016/077315 2016-09-15 2016-09-15 Inhibiteur d'accumulation de graisse, inhibiteur de différenciation de pré-adipocytes, agent de réduction de graisse viscérale et aliment ou boisson pour la réduction de graisse viscérale WO2018051471A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PCT/JP2016/077315 WO2018051471A1 (fr) 2016-09-15 2016-09-15 Inhibiteur d'accumulation de graisse, inhibiteur de différenciation de pré-adipocytes, agent de réduction de graisse viscérale et aliment ou boisson pour la réduction de graisse viscérale
KR1020197010469A KR102239331B1 (ko) 2016-09-15 2016-09-15 지방 축적 억제제, 지방 전구 세포의 분화 억제제, 내장 지방 저감제 및 내장 지방 저감용 음식품
JP2018539460A JP6752285B2 (ja) 2016-09-15 2016-09-15 脂肪蓄積抑制剤、脂肪前駆細胞の分化抑制剤、内臓脂肪低減剤、及び内臓脂肪低減用飲食品

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2016/077315 WO2018051471A1 (fr) 2016-09-15 2016-09-15 Inhibiteur d'accumulation de graisse, inhibiteur de différenciation de pré-adipocytes, agent de réduction de graisse viscérale et aliment ou boisson pour la réduction de graisse viscérale

Publications (1)

Publication Number Publication Date
WO2018051471A1 true WO2018051471A1 (fr) 2018-03-22

Family

ID=61618724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/077315 WO2018051471A1 (fr) 2016-09-15 2016-09-15 Inhibiteur d'accumulation de graisse, inhibiteur de différenciation de pré-adipocytes, agent de réduction de graisse viscérale et aliment ou boisson pour la réduction de graisse viscérale

Country Status (3)

Country Link
JP (1) JP6752285B2 (fr)
KR (1) KR102239331B1 (fr)
WO (1) WO2018051471A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3764364A4 (fr) * 2018-03-29 2021-12-15 Tanita Corporation Dispositif de détermination de composants, procédé de détermination de composant et programme

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230077613A (ko) 2021-11-25 2023-06-01 (주)네오크레마 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도
KR20230077611A (ko) 2021-11-25 2023-06-01 (주)네오크레마 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039270A1 (fr) * 2001-11-08 2003-05-15 The Nisshin Oillio,Ltd. Aliments et boissons agissant contre l'obesite
JP2009023911A (ja) * 2007-07-17 2009-02-05 Nihon Nosan Kogyo Kk 抗加齢用組成物
WO2011145722A1 (fr) * 2010-05-20 2011-11-24 Miyazaki Toru Procédé de criblage de composés qui contrôlent la fonction d'aim
JP2015189691A (ja) * 2014-03-27 2015-11-02 公益財団法人東洋食品研究所 Ｇｐｄｈ活性抑制剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830001810B1 (ko) * 1980-10-28 1983-09-12 니혼노오산 고오교 가부시끼가이샤 지질대사 개선작용을 갖는 요오드 고함유란의 생산방법
JP4363825B2 (ja) 2002-08-22 2009-11-11 株式会社ファンケル 脂肪細胞分化抑制剤
JP4675781B2 (ja) 2006-01-11 2011-04-27 日本メナード化粧品株式会社 脂肪細胞分化抑制剤
JP2011225496A (ja) 2010-04-22 2011-11-10 Q P Corp 体脂肪蓄積抑制剤、内臓脂肪蓄積抑制剤、肝臓中トリグリセリド上昇抑制剤、又は血中トリグリセリド上昇抑制剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039270A1 (fr) * 2001-11-08 2003-05-15 The Nisshin Oillio,Ltd. Aliments et boissons agissant contre l'obesite
JP2009023911A (ja) * 2007-07-17 2009-02-05 Nihon Nosan Kogyo Kk 抗加齢用組成物
WO2011145722A1 (fr) * 2010-05-20 2011-11-24 Miyazaki Toru Procédé de criblage de composés qui contrôlent la fonction d'aim
JP2015189691A (ja) * 2014-03-27 2015-11-02 公益財団法人東洋食品研究所 Ｇｐｄｈ活性抑制剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE 121ST JAPANESE SOCIETY ZOOTECHNICAL SCIENCE ANNUAL MEETING ABSTRACTS, 27 March 2016 (2016-03-27), pages 244 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3764364A4 (fr) * 2018-03-29 2021-12-15 Tanita Corporation Dispositif de détermination de composants, procédé de détermination de composant et programme

Also Published As

Publication number Publication date
KR20190053221A (ko) 2019-05-17
KR102239331B1 (ko) 2021-04-12
JPWO2018051471A1 (ja) 2019-07-18
JP6752285B2 (ja) 2020-09-09

Similar Documents

Publication Publication Date Title
JP6752285B2 (ja) 脂肪蓄積抑制剤、脂肪前駆細胞の分化抑制剤、内臓脂肪低減剤、及び内臓脂肪低減用飲食品
EP2992933B1 (fr) Ginsénoside f2 pour la prophylaxie et le traitement d'une maladie du foie
CN114126599A (zh) 改变衰老相关分泌表型的方法和组合物
An et al. Antiobesity and antidiabetic effects of the dairy bacterium Propionibacterium freudenreichii MJ2 in high-fat diet-induced obese mice by modulating lipid metabolism
JP5389434B2 (ja) アディポネクチン発現低下抑制剤及びその用途
US20220175713A1 (en) Depside trimeric compounds for skeletal muscle modulation
JP6488504B2 (ja) 褐色脂肪細胞分化誘導剤及びその用途
JP5923381B2 (ja) ＰＰＡＲγ活性抑制剤
EP3616705A2 (fr) Composition pour améliorer la prévention et le traitement du foie gras contenant un extrait d'amomum vilosum
KR101232872B1 (ko) 스핑고신-1-포스페이트（ｓｐｈｉｎｇｏｓｉｎｅ－１－ｐｈｏｓｐｈａｔｅ） 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 예방 및 치료용 약학적 조성물
JP2007039367A (ja) 細胞の分化を促進する組成物およびその利用
Hosseini et al. Impact of short–term intake of Cinnamon on serum glucose and lipid profile in patients with type 2 diabetes mellitus
JPWO2008136173A1 (ja) スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤
US20220054448A1 (en) Novel polymethoxyflavone compounds for skeletal muscle modulation, methods and uses thereof
JP2008063279A (ja) 血糖上昇予防・治療剤
JP2012171916A (ja) 体脂肪低減剤及び体脂肪低減食品
KR20100028616A (ko) 비만 개선용 경구 조성물
JP2008031154A (ja) 血糖低下剤
JP6192141B1 (ja) 骨量減少抑制剤、及びそれを有効成分とする骨粗鬆症の予防又は改善剤
WO2020066158A1 (fr) Inhibiteur d'accumulation de graisse et agent améliorant le taux de lipides dans le sang
JP5998312B2 (ja) オキアミの水溶性抽出物の薬理用途
TW202222329A (zh) 增加肌肉量、增加肌力、抑制肌肉量減少或抑制肌力下降用組成物
KR20240003289A (ko) 햄프씨드오일을 함유하는 대사성 질환 개선용 기능성 식품
TW202227114A (zh) Ｔｇｒ５活化用組成物
KR20210091211A (ko) D-알룰로오스를 유효 성분으로 하는 갈색 지방·베이지 지방 세포 활성화제

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16916252

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018539460

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197010469

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 16916252

Country of ref document: EP

Kind code of ref document: A1